Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

pomalidomide

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

TNFα inhibitor, NK cell stimulant, IL-6 inhibitor, IL-10 stimulant, IL-1β inhibitor

Related drugs:

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval pomalidomide + daratumumab / hyaluronidase Sensitive : A1	pomalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval pomalidomide + daratumumab / hyaluronidase Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor + pomalidomide Sensitive: A2 - Guideline selinexor + pomalidomide Sensitive : A2	selinexor + pomalidomide Sensitive: A2 - Guideline selinexor + pomalidomide Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ixazomib + pomalidomide Sensitive: A2 - Guideline ixazomib + pomalidomide Sensitive : A2	ixazomib + pomalidomide Sensitive: A2 - Guideline ixazomib + pomalidomide Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide Sensitive: A2 - Guideline pomalidomide Sensitive : A2	pomalidomide Sensitive: A2 - Guideline pomalidomide Sensitive : A2
No biomarker	Lymphoma	No biomarker	Lymphoma	pomalidomide Sensitive: A2 - Guideline pomalidomide Sensitive : A2	pomalidomide Sensitive: A2 - Guideline pomalidomide Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib + pomalidomide Sensitive: A2 - Guideline carfilzomib + pomalidomide Sensitive : A2	carfilzomib + pomalidomide Sensitive: A2 - Guideline carfilzomib + pomalidomide Sensitive : A2
Chr amplification(1)(q21)	Multiple Myeloma	Chr amplification(1)(q21)	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: B - Late Trials pomalidomide + isatuximab-irfc Sensitive : B	pomalidomide + isatuximab-irfc Sensitive: B - Late Trials pomalidomide + isatuximab-irfc Sensitive : B
CRBN underexpression	Multiple Myeloma	CRBN underexpression	Multiple Myeloma	pomalidomide Resistant: C3 – Early Trials pomalidomide Resistant : C3	pomalidomide Resistant: C3 – Early Trials pomalidomide Resistant : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	pomalidomide Sensitive: C3 – Early Trials pomalidomide Sensitive : C3	pomalidomide Sensitive: C3 – Early Trials pomalidomide Sensitive : C3
KRAS mutation	Multiple Myeloma	KRAS mutation	Multiple Myeloma	trametinib + daratumumab + pomalidomide Sensitive: C4 – Case Studies trametinib + daratumumab + pomalidomide Sensitive : C4	trametinib + daratumumab + pomalidomide Sensitive: C4 – Case Studies trametinib + daratumumab + pomalidomide Sensitive : C4